Serono Fights Biogen's Retrial Bid Over Nixed MS Drug Patent
A New Jersey federal jury rightly found that a Biogen MA Inc. patent covering its multiple sclerosis treatment Avonex was invalid, because while the patent covered a new process, the treatment...To view the full article, register now.
Already a subscriber? Click here to view full article